Biocon Group chairperson Kiran Mazumdar-Shaw predicts FY26 as a growth year, fueled by biosimilars, generics, and research ...

Kiran Mazumdar-Shaw discusses the impact of US drug price reduction efforts on Indian pharma, Biocon's US expansion, strong ...

Biosimilars, too, are expected to gain ground as healthcare systems worldwide look for cost-effective alternatives to ...

The Chairperson of Biocon Group said that generics and biosimilars are clearly part of the Affordable Care Act, but they are not the target of President Trump's current efforts.

Kiran Mazumdar-Shaw suggestion was met with a flurry of responses, with many users pushing back against the idea.

said Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon, adding that one needs to wait for more details on the order to ascertain the full impact. Speaking to CNBC TV18 on May 13 ...

Shaw highlighted the importance of elevating this sector in line with Prime Minister Narendra Modi’s vision of a globally ...

the board was of the opinion that we should look at other strategic options which also be includes evaluating a merger," Kiran Mazumdar-Shaw, chairperson, Biocon Group, told investors in an ...

In an interaction with The Free Press Journal, we asked Biocon Founder and global business leader Kiran Mazumdar-Shaw about ...

Shaw, investor Mohandas Pai, and BJP leaders including MP Tejasvi Surya and MLA S Suresh Kumar have urged the Karnataka ...

Biocon and Biocon Biologics Executive Chairperson, Kiran Mazumdar-Shaw, says they're adding capacity at their insulin ...